trial

Brain Circuitry Therapeutics for Schizophrenia

NCTId NCT06341517
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 70 (estimated)
Sponsored by Indrit Begue
Primary completion 2026-09-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
70 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-04-15
Primary completion
2026-09-25
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
iTBS

Sponsors

Indrit BegueLead Sponsor
University of Geneva, SwitzerlandCollaborator

Sites

2 total
Geneva, SwitzerlandGeneva, Switzerland

Facts & assertions

4 sourced
Enrollment
70
Phase
NA
Primary Completion Date
2026-09-25
Status
RECRUITING
relationships
The graph out of here
drug
iTBS
drug
lead_sponsor
Indrit Begue
company
collaborator
University of Geneva, Switzerland
company
indication
Schizophrenia; Psychosis
indication
Schizophrenia
indication
Psychotic Disorders
indication